Literature DB >> 9427691

High efficiency adenovirus-mediated gene transfer to human dendritic cells.

A B Dietz1, S Vuk-Pavlović.   

Abstract

The interest in the use of human dendritic cells in cancer immunotherapy calls for efficient ex vivo methods of dendritic cell education. To extend the range of methods available, we generated phenotypically characteristic dendritic cells from peripheral blood monocytes incubated with granulocyte-macrophage colony-stimulating factor and interleukin-4 and infected them with an adenovirus containing a humanized version of green fluorescent protein as a marker of gene expression. The levels of expressed protein were high, but they were further increased in combination with cationic liposomes. In comparison to transfection efficiency of the homologous expression plasmid, adenovirus-mediated gene transfer was substantially more efficient. With the aid of liposome-mediated infection, gene transfer into CD83+ dendritic cells was highly effective, resulting in more than 90% of the cells expressing the transgene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427691

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.

Authors:  T Yoshida; K Okuda; K Q Xin; K Tadokoro; J Fukushima; S Toda; E Hagiwara; K Hamajima; T Koshino; T Saito
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach.

Authors:  B M Foxwell; S Yoshimura; J Bondeson; F M Brennan; M Feldmann
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

3.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 4.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

Review 5.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Authors:  David W O'Neill; Nina Bhardwaj
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

Review 6.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 7.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

8.  Genetically targeted adenovirus vector directed to CD40-expressing cells.

Authors:  Natalya Belousova; Nikolay Korokhov; Valentina Krendelshchikova; Vera Simonenko; Galina Mikheeva; Pierre L Triozzi; Wayne A Aldrich; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design.

Authors:  Mehran Gholamin; Omeed Moaven; Moein Farshchian; Mahmoud Mahmoudi; Mojtaba Sankian; Bahram Memar; Mohammad Naser Forghani; Reza Malekzadeh; Mohammad Taghi Rajabi-Mashhadi; Mohammad Reza Abbaszadegan
Journal:  BMC Cancer       Date:  2010-06-07       Impact factor: 4.430

10.  Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Authors:  Takuya Osada; Christopher Y Woo; Matthew McKinney; Xiao Yi Yang; Gangjun Lei; Heather G Labreche; Zachary C Hartman; Donna Niedzwiecki; Nelson Chao; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.